|
MONDAY,
MARCH 26, 2001
|
09:00-10:45
 |
S1
OPTIMAL PREVENTIONOF MEASLES AND VARICELLA IN EUROPE
Pre-Meeting Symposum sponsored by: AVENTIS PASTEUR MSD
Chairperson: F.
Zepp, Germany
Co-Chairperson: L. Hessel, France |
HALL
A |
| 09:00 |
INTRODUCTION
F. Zepp*, Germany
L. Hessel*, France |
|
| 09:10 |
MEASLES
CAN BE ELIMINATED, BUT CAN THE VIRUS BE ERADICATED?
H. Peltola*, Finland |
|
| 09:30 |
UNDER-APPRECIATED
PUBLIC HEALTH BENEFITS OF VARICELLA VACCINATION
L. Notarangelo*, Italy |
|
| 09:50 |
CLINICAL
EXPERIENCE WITH VARIVAX
P. Larussa*, USA |
|
| 10:10 |
THE
CHALLENGE OF DEVELOPING A MMR-V COMBINATION VACCINE
A.R. Shaw*, USA |
|
| 10:30 |
PANEL
DISCUSSION: ENSURING OPTIMAL PREVENTION OF MEASLES AND VARICELLA IN
EUROPE
Moderators:
F. Zepp*, Germany
L. Hessel*, France |
|
| 10:45 |
Coffee
Break and Exhibition Visit |
|
| 11:15-13:00 |
S2
EPIDEMIOLOGICAL BASIS FOR DISEASE CONTROL
Pre-Meeting Symposium sponosred by: GLAXOSMITHKLINE BIOLOGICALS
Chairpersons: P.
Van Damme, Belgium
H. Bogaerts, Belgium |
HALL
A |
| 11:15 |
INTRODUCTION
H. Bogaerts*, Belgium |
|
| 11:20 |
THE
CASE FOR UNIVERSAL VACCINATION AGAINST HEPATITIS A AND B
P. Van Damme*, Belgium |
|
| 11:40 |
FINAL
STAGES OF GLOBAL ERADICATIONOF POLIO
T.J. John*, India |
|
| 12:00 |
VARICELLA
VACCINE: THE US APPROACH
A.A. Gershon*, USA |
|
| 12:10 |
MANAGING
VARICELLA - AN EXAMPLE FOR EUROPE
P. Wutzler*, Germany |
|
| 12:20 |
STRATEGIC
USE OF EPIDEMIOLOGY IN WHO'S VACCINE PROGRAMMES
J. Clements*, Switzerland |
|
| 12:50 |
QUESTIONS
AND ANSWERS |
|
| 13:00 |
Lunch
Break |
|
| 14:00-15:15 |
S3
CONTROVERSIES IN PEDIATRIC URTLs: NEW PERSPECTIVES FROM RECENT DATA
Pre-Meeting Symposium sponsored by: PFIZER INC.
Chairperson: G.
Kanra, Turkey |
HALL
A |
| 14:00 |
INTRODUCTION
G. Kanra*, Turkey |
|
| 14:05 |
GROUP
A STREPTOCOCCAL PHARYNGITIS
R. Cohen*, France |
|
| 14:30 |
RATIONAL
THERAPEUTICS IN ACUTE OTITIS MEDIA
E.J. O'Rourke*, USA |
|
| 14:55 |
PANEL
DISCUSSION AND QUESTIONS |
|
| 15:10 |
SUMMARY
G. Kanra*, Turkey |
|
| 15:15 |
Coffee
Break and Exhibition Visit |
|
| 15:45-17:30 |
S4
CONJUGATED PNEUMOCOCCAL VACCINES: A NEW STRATEGY FOR PREVENTION AND
PROTECTION AGAINST PAEDIATRIC INFECTIOUS DISEASES
Pre-Meeting Symposium sponsored by: WYETH LEDERLE VACCINES
Chairperson: H.J.
Schmitt, Germany |
HALL
A |
| 15:45 |
INTRODUCTION
H.J. Schmitt*, Germany |
|
| 15:50 |
GLOBAL
COMPARISON OF INVASIVE AND NONINVASIVE PNEUMOCOCCAL DISEASE
B. Fritzell*, France |
|
| 16:05 |
NEED
FOR PNCRM7 (PREVENAR®, PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE) IN
EUROPE: EFFICACY AGAINST INVASIVE PNEUMOCOCCAL DISEASE
H.J. Schmitt*, Germany |
|
| 16:25 |
ROLE
OF PNCRM7 (PREVENAR®) IN THE PREVENTION OF PNEUMOCOCCAL OTITIS MEDIA
H. Nohynek*, Finland |
|
| 16:40 |
EFFECT
OF PNEUMOCOCCAL CONJUGATE VACCINES ON CARRIAGE AND TRANSMISSION OF
STREPTOCOCCUS PNEUMONIAE AND HERD IMMUNITY
K.P. Klugman*, USA |
|
| 17:00 |
ANTIBIOTIC
RESISTANCE, DAY CARE ATTENDANCE, AND OTITIS MEDIA: THE NEED TO CHANGE
ANTIBIOTIC PRESCRIBING PATTERNS
R. Dagan*, Israel |
|
| 17:20 |
QUESTIONS
AND ANSWERS |
|
